NCT07528040
An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Not Yet Recruiting · Not specified · Shanghai 10th People's Hospital · registry updated 2026-04-14
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The goal of this single arm,non-interventional, prospective, descriptive study is to evaluate the efficacy of guselkumab treatment in preventing endoscopic recurrence of Crohn's Disease in adult participants who have a documented diagnosis of moderate to severe CD and have undergone an ileocolonic surgical resection. The primary endpoint is Endoscopic recurrence rate at week24.
Inclusion
- Patients≥ 18，
- Have a documented diagnosis of moderate to severe CD
- Have undergone an ileocolonic surgical resection
Exclusion
- Has complications of CD, such as short bowel syndrome Currently has or is suspected to have an abscess
- Active infection
- Currently has a malignancy or has a history of malignancy within 5 years